rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BPC-157 Reduces Side Effects of Antipsychotic Drugs: Less Muscle Stiffness and Fewer Stomach Ulcers

RPEP-005281999Jelovac, N; Sikiric, P; Rucman, R; Petek, M; Marovic, A; Perovic, D; Seiwerth, S; Mise, S; Turkovic, B; Dodig, G; Miklic, P; Buljat, G; Prkacin, I
Animal StudyPreliminary evidence
The takeaway

BPC-157 reduced both catalepsy (muscle stiffness) and gastric ulcers caused by antipsychotic drugs haloperidol, fluphenazine, and reserpine in mice and rats at microgram and nanogram doses.

3 antipsychotics

BPC-157 reduced side effects from haloperidol, fluphenazine, AND reserpine — three mechanistically different drugs

What the researchers found

BPC-157 attenuated catalepsy and gastric ulcers induced by haloperidol, fluphenazine, and reserpine at both 10 μg/kg and 10 ng/kg doses, demonstrating broad protective effects against neuroleptic side effects.

Why it matters

Antipsychotic side effects are a major reason patients stop taking their medication. A co-treatment that reduces muscle stiffness and stomach damage without interfering with antipsychotic efficacy could dramatically improve treatment adherence.

How the study worked

Animal studies in mice and rats. BPC-157 was administered IP at two doses alongside haloperidol, fluphenazine, or reserpine. Catalepsy was measured by bar test, and gastric lesions were scored macroscopically.

What this study cannot tell us

Animal study. Whether BPC-157 would interfere with the antipsychotic therapeutic effect was not conclusively assessed. Translation to human psychiatric care is speculative.

How to read the evidence

Preliminary animal evidence across multiple drug challenges with consistent protective effects, but no human data or mechanism confirmation.

When this study was published

Published in 1999. BPC-157's dopamine-related effects have been studied further in animal models, but clinical studies for neuroleptic side effect protection have not been conducted.

The bigger picture

BPC-157's ability to counteract dopamine-related side effects while its studies show it modulates (not blocks) the dopamine system suggests it acts as a system stabilizer rather than a simple antagonist, a unique pharmacological profile.

Questions still open

  • Does BPC-157 reduce antipsychotic side effects without diminishing therapeutic efficacy?
  • Could BPC-157 prevent tardive dyskinesia from long-term antipsychotic use?
  • What is BPC-157's exact mechanism of dopamine system modulation?

Common questions

What is catalepsy from antipsychotics?
Catalepsy is severe muscle stiffness that makes it difficult to move. It's caused by antipsychotic drugs blocking dopamine, and it's related to the movement side effects (extrapyramidal symptoms) that make many patients stop their medication.
How does BPC-157 work here if it's a gut peptide?
BPC-157 was originally found in stomach juice, but it has effects throughout the body. Its interaction with the dopamine system appears to stabilize rather than simply block dopamine signaling, which may explain how it reduces side effects from dopamine-blocking drugs.

Read the original research

Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.

European journal of pharmacology, 379(1), 19-31

View on PubMed ↗

Citation

Jelovac, N; Sikiric, P; Rucman, R; Petek, M; Marovic, A; Perovic, D; Seiwerth, S; Mise, S; Turkovic, B; Dodig, G; Miklic, P; Buljat, G; Prkacin, I. (1999). Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.. European journal of pharmacology, 379(1), 19-31.